Development and implementation of a COVID-19 convalescent plasma program in a middle-income economy
Authors:
- Gustavo de Carvalho DuarteGDGustavo de Carvalho Duarte
- Vivian SimoniVSVivian Simoni
- Glaciano Nogueira RibeiroGRGlaciano Nogueira Ribeiro
- Ricardo HaddadRHRicardo Haddad
- Mariangela MoschenMMMariangela Moschen
- Rodrigo Spessotto Morais ToledoRTRodrigo Spessotto Morais Toledo
- Maria Angela Pignata OttoboniMOMaria Angela Pignata Ottoboni
- Alfredo Mendrone-JuniorAMAlfredo Mendrone-Junior
- Dante Mario LanghiDLDante Mario Langhi
Open Access
- 19 January 2022
- journal article
- research article
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 206-212
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Coronaviruses pandemics: Can neutralizing antibodies help?Life Sciences, 2020
- Guidance for the procurement of COVID‐19 convalescent plasma: differences between high‐ and low‐middle‐income countriesVox Sanguinis, 2020
- Deployment of convalescent plasma for the prevention and treatment of COVID-19Journal of Clinical Investigation, 2020
- COVID‐19 and ABO blood group: another viewpointBritish Journal of Haematology, 2020
- Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samplesEurosurveillance, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Convalescent plasma as a potential therapy for COVID-19The Lancet Infectious Diseases, 2020
- COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in BrazilThe Brazilian Journal of Infectious Diseases, 2020
- Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studiesVirology Journal, 2018
- Disappearance of Antibodies to SARS-Associated Coronavirus after RecoveryNew England Journal of Medicine, 2007